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Available online	Tetrazolo- and 1,2,4-oxadiazolo-fused derivatives of the antitumour, antibiotic, DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines and their pyrrolobenzothiadiazepine derivatives have been produced as analogues of a 1,2,3-triazolo-fused  pyrrolobenzothiadiazepine which was shown to be a Glut-1 transporter inhibitor with potential as an antitumour agent. The tetrazolo-fused systems were produced by intramolecular 1,3-dipolar cycloaddition between an azide and a nitrile. The 1,2,4-oxadiazolo systems were produced by nitrile oxide cycloadditions to  pyrrolobenzothiadiazepines which were in turn produced from a 2-(azidobenzenesulfonyl)-1,2-thiazine 1-oxide. The latter species underwent a phosphite mediated one-pot sulfur extrusion, ring contraction and azide to amine conversion to form 1-(aminobenzenesulfonyl)pyrroles. Bischler-Napieralski ring closure gave the pyrrolobenzothiadiazepines.
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1. Introduction
The pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) are important DNA-interactive agents that show sequence specificity and have attracted attention as antitumour compounds and as antibiotics.1 Amongst the first PBDs that attracted interest were natural products such as abbeymycin (1),2 neothramycins A/B (2a/2b)3 and DC-81 (2c),4 as well as more recent examples such as limazepine C (3),5 as shown in Figure 1. Numerous synthetic analogues have been produced including PBD-based antitumour drug hybrids6 and, most notably, dimeric PBD analogues7 such as SJG-136 (4) which has entered phase II clinical trials. The synthesis and biological activity of the PBDs has been the subject of comprehensive reviews2 and continues to attract the attention of numerous research groups.8 These PBDs are all electrophilic at C11 and alkylate DNA via binding the amine group of guanine residues in the minor groove of DNA, a process facilitated by the S​-stereocentre at C11a which enables a right-handed twist into the DNA minor groove.2 The fuligocandins, of which fuligocandin B (5) [Figure 1] is typical, constitute a second, less-studied, class of PBD natural products that attract interest since some members sensitise leukemia cells to apoptosis caused by a tumour necrosis factor-related apoptosis-inducing ligand signalling pathway.9,10 The circumdatins such as circumdatins H and  J  (6a/6b) are quinazalino-PBDs, and these and similar annulated systems have attracted attention due to antitumour, antibiotic and insecticidal properties.11,12 It is noteworthy that tetracyclic PBDs such as the imidazo-fused bretazenil (7a)13 and related systems 7b/c,14 the 1,2,4-triazolo-fused systems 8,15 and the 1,2,3-triazolo system 916 have attracted interest as cognition enhancers, cytotoxic agents, and protease inhibitors, respectively. Pyrazolo-fused PBDs,17 and the aziridino-fused system 10a,18 which is of interest due to its electrophilic C11, have also appeared. The synthesis and biological properties of the analogous sulfur/sulfonamide containing pyrrolo[1,2-b][1,2,5]benzothiadiazepines (the PBTDs) have attracted considerably less attention since their first appearance.19,20 Figure 1 shows some examples of this system. Artico and Silvestri have shown that PBTDs 11-1321,22 are of interest as non-nucleosidic reverse transcriptase inhibitors,21 and went on later to show that PBTDs such as compound 14 showed high apoptotic activity in human BCR-ABL-expressing leukemia cells and in primary leukemia blasts from chronic myeloid leukemic (CML) patients.23 [BCR - cellular breakpoint cluster region gene; ABL - Abelson murine leukemia oncogene]. The PBTDs also induced cell death in primary leukemia cells obtained from CML patients who were imatinib-resistant, imatinib being a key part of the current treatment regime for patients with CML. These PBTDs were shown to influence the activation of caspase-9 and -3 cascades showing characteristic cleavage of poly(ADP-ribose) polymerase (PARP), and to induce apoptosis before BCR-ABL protein expression and tyrosine phosphorylation levels were affected. As part of a programme of work that is exploring the synthesis of biologically active PBD and PBTD analogues,16a,18,24 this paper concerns the synthesis (and attempted synthesis) of tetracyclic PBD and PBTD analogues, and will focus firstly on tetrazolo-fused PBD and PBTD systems obtained by intramolecular 1,3-dipolar cycloaddition of  azide to nitrile. We are aware of several reports that have produced tricyclic tetrazolo-fused 1,4-benzodiazepines.25 However, only one report26a has come to our attention concerning the pyrrolo[1,2-a]tetrazolo[5,1-c]benzodiazepine targeted here, although it was not accessed by intramolecular 1,3-dipolar cycloaddition. The isomeric pyrrolo[1,2-a]tetrazolo[1,5-d]benzodiazepine derivative 15 has been accessed by intramolecular 1,3-dipolar cycloaddition,26b but is not the isomer targeted in our work. We are aware of no approaches to the tetracyclic tetrazolo-fused PBTDs. An interest in 1,2,4-oxadiazoles27,28 also led us to explore the synthesis of 1,2,4-oxadiazolo-fused PBTD systems. Whilst oxadiazolo-1,4-benzodiazepines29 and PBDs26a,30 are known, we are aware of no examples of the tetracyclic oxadiazolo-PBTD sulfonamide analogues targeted in this work and described below. The only tetracyclic PBTDs of any type of which we are aware are the aziridino-fused 10b18 and triazolo-fused 16,16a both from our earlier work, and the pyrazolo- and imidazolo-fused 13,21,22 and piperazino-fused systems 1722b of Artico, along with an azetidino-fused PBTD22c used by Artico in the synthesis of a (tricyclic) spiro-PBTD derivative.
  
   Figure 1: Pyrrolobenzodiazepines and Pyrrolobenzothiadiazepines

2. Results and Discussion
In a previous preliminary communication,16a summarised in Scheme 1, we showed that the triazolo-fused PBDs and PBTDs 21a-c were easily available from the intramolecular ‘click’ reaction of the corresponding alkynyl azide derivatives 20. The alkynes 20 were obtained by reaction of the prolinal derived aldehydes 18a-c with the Bestmann-Ohira reagent (19). It was notable that alkyne formation and ‘click’ reaction proceeded in a cascade process without isolation of the alkyne. The use of amino acid derived aldehydes other than prolinal allowed access to tricyclic analogues 22. Similar approaches to triazolo-fused systems appeared shortly before16b and after25b,31 our report. We have found that one of this tetracyclic series, the triazolo-PBTD compound 21a (X = SO2, R1 = R2 = H), exhibits Glut-1 dependent toxicity which suggests32 that it may have potential as an anticancer agent. In order to determine the dependence of the toxicity of 21a (X = SO2, R1 = R2 = H) on Glut-1 transporter distribution, a clonogenic assay was carried out using a Glut-1 over expressing HT1080 cell line, with a wild type HT1080 cell line as a control.33 Cells were cultured in DMEM media (4500mg/L glucose), 10% foetal bovine serum and 1% penicillin and streptomycin. The assay was also conducted in DMEM with 0% glucose to establish whether the availability of glucose affected the toxicity of the drug. This Glut-1 dependent toxicity was diminished in the absence of glucose therefore suggesting that dependency may be lost in low glucose concentrations found in tumours. This encouraging result led to a need to synthesise other analogues of tetracyclic PBDs and PBTDs. In this paper, we report the synthesis of two such series, tetrazolo-PBDs/PBTDs and 1,2,4-oxadiazolo-PBTDs.

Scheme 1: Synthesis of 1,2,3-Triazolo-PBD and PBTDs

We accessed a short series of tetrazolo-PBDs and PBTDs 29a-c from intramolecular azide-nitrile 1,3-dipolar cycloaddition, as shown in Scheme 2. Tetrazolo-PBDs and PBTDs 29a-c were produced by heating the azido nitriles 28a-c in toluene for 24 hours. Compound 29c was chosen due to the benzene substitution pattern present in the biologically active pyrrolobenzodiazepines 2a-c and 4. The nitrile compounds 28a-c were obtained by several routes: (i) in situ dehydration of the non-isolated prolinamide-derived amides/sulfonamide 24 using an excess of the acid chloride 23; (ii) by conversion of proline-derived carboxylic acids 25 into the isolated amide 24 using standard coupling protocols, followed by dehydration of the amide with tosyl chloride; (iii) by dehydration of the oxime 26 obtained from the reaction of the prolinal-derived aldehydes 18 with hydroxylamine; (iv) by the direct conversion of the prolinol-derived alcohols 27 into the nitrile 28 after treatment with iodine in aqueous ammonia. We found procedures (i) and (iv) to be the most convenient for the conversion of the acid chloride 23a into nitrile 28a (36% and 48%, respectively). Procedure (ii) was most efficient (two steps, 62% and 74% yield) for the conversion of the sulfonyl chloride 23b into nitrile 28b. Procedure (i) was the best procedure the synthesis of nitrile 28c (56% from precursor 23c). We found that procedure (iii) gave unreliable results. Each of the azido nitrile compounds 28a-c gave a clean intramolecular 1,3-dipolar cycloaddition reaction to give the desired tetrazoles 29a-c in yields of 99, 100 and 58%, respectively. The conversion of compounds 28a-c into 29a-c was apparent from the infra-red spectra of the products which showed loss of the distinctive azide and nitrile stretches. It should be noted that compound 29a has been reported by another group,26a but was not accessed by intramolecular 1,3-dipolar cycloaddition, but instead from the sequential reaction of a pre-formed pyrrolo[1,4]benzodiazepin-2-thione with hydrazine and then sodium azide. 


Scheme 2: Synthesis of Tetrazolo-PBD and PBTDs
Reagents and Conditions: (a) excess 23, L-prolinamide, K2CO3 (aq.), CH2Cl2, 4 h, room temp.; (b) L-proline, K2CO3 (aq.), CH2Cl2, 14 h, room temp.; (c) BOP, NH4Cl, Et3N; (d) p-TsCl, pyridine, heat; (e) L-prolinol, K2CO3 (aq.), CH2Cl2, 4 h, room temp.; (f) Swern oxidation; (g) NH2OH·HCl, NaOAc, EtOH, reflux. (h) I2/aq. NH3, 70 ºC, 20 h. 

In our studies with alkynes (Scheme 1),16a we found that systems derived from amino acids other than proline behaved predictably in the alkyne to azide cycloaddition and gave the expected triazolo-fused benzodiazepines and benzothiadiazepines 22 shown in Scheme 1. Thus, we next explored the reactivity of the nitriles 30a and b. These were obtained by coupling the appropriate amino acid with the acid chloride 23a (X = CO, R1 = R2 = H), conversion to the amide with BOP/NH4Cl and dehydration with tosyl chloride.  We found that these gave the benzodiazepines 31a/b shown in Scheme 3, rather than the desired tetrazolobenzodiazepines 32. Structural assignment was based upon the presence of an NH2 group in the infra-red and 1H NMR spectra and consistent mass measurements (loss of two nitrogen atoms) together with loss of the distinctive azide and nitrile stretches in the infra-red spectra. We assume that this reaction proceeds via conversion of the azide into a nitrene or amine with subsequent attack of the nitrile by the amine/nitrene nitrogen, and tautomerism to give the amidine 31. The sulfonyl analogues also failed to give the desired tetrazoles, and the failure of this reaction to produce tetrazolo systems by intramolecular cycloaddition meant that we did not explore this route further – the synthesis of 2-amino-1,4-benzodiazepine derivatives of this type by amine cyclisation onto the nitrile group is known, the amines being accessed by nitro reduction.34


Scheme 3: Synthesis of Tetrazolo-PBD and PBTDs

Having now shown that nitriles as well as alkynes undergo intramolecular 1,3-dipolar cycloaddition, we next sought to explore the reactivity of the imines 33 (Scheme 4). However, attempts to study these compounds were thwarted by our failure to form stable imines 33 from the reaction of the aldehydes 18a/b (X = CO or SO2) with alkyl or aryl amines. Luckily, as part of our work above (see Scheme 2), we knew that the oxime 26a was stable meaning that the potential of the azide to oxime intramolecular cycloaddition could be explored. Heating compound 26a in toluene (Scheme 4) led to the formation of the hydroxyamino-pyrrolobenzodiazepine 34a in 32% yield. The formation of this product is consistent with either intramolecular 1,3-dipolar cycloaddition followed by nitrogen extrusion and diradical rearrangement (route a, Scheme 4), or nitrogen extrusion followed by nitrene insertion and diradical rearrangement (route b, Scheme 4). All attempts to convert compound 34a (X = CO) into the oxadiazolino-PBD derivative 35a (X = CO) by reaction with a phosgene equivalent were unsuccessful, a disappointment given that the corresponding thione 34b (X = CS) is known to give the oxadiazolino-PBD thione 35b (X = CS) upon reaction with diphosgene.26a In addition to compound 35b26a there are other reports30 of oxadiazolo-PBDs. However, we are aware of no approaches to the analogous oxadiazolo-PBTDs and hence sought to access this novel PBTD system in order to assess its activity as a Glut-1 transporter inhibitor due to our success with the triazolo-PBTD compound 21a (see above). Thus, we attempted to prepare the oxime of aldehyde 18b (X = SO2), with a view to obtaining hydroxyamino-pyrrolobenzothiadiazepine 34c and thence the oxadiazolo-PBTD 35c. This approach was unsuccessful and led only to the isolation of the nitrile 28b (shown in Scheme 2) upon reaction of the aldehyde 18b with hydroxylamine. An alternative approach to the oxadiazolo-PBTDs was hence sought. 



Scheme 4: Synthesis of the Hydroxyamino-PBD 34a 

Our successful alternative strategy is shown in Scheme 5. We were able to produce a series of compounds 40a-d with the previously unknown oxadiazolopyrrolobenzothiadiazepine nucleus by using an intermolecular reaction between the pyrrolobenzothiadiazepines 39a/b and nitrile oxides. We produced the required pyrrolobenzothiadiazepines 39 using the 1,2-thiazine 1-oxide ring-contraction methodology that we reported in a preliminary fashion previously.24 Thus, as shown in Scheme 5, hetero-Diels-Alder reaction of the sulfinylimine 36 with isoprene or 2,3-dimethyl-1,3-butadiene gave the 1,2-thiazine 1-oxides 37. A one-pot phosphite-mediated sulfur-extrusion and ring-contraction with concomitant Staudinger-type azide to amine transformation gave the 1-aminoaryl-pyrroles 38. The ring contraction was very clearly indicated by loss of the methylene groups from the 1,2-thiazine 1-oxides and the appearance of the additional methine groups of the pyrrole ring in the aromatic region of the 1H and 13C NMR spectra. Infra-red and 1H NMR spectra confirmed the conversion of the azide into the primary amine. N-Formylation with a preformed mixture of acetic anhydride and formic acid followed by Bischler-Napieralski ring closure gave the required pyrrolobenzothiadiazepines 39a and b, with the additional CH group apparent at 8.6 – 8.7 ppm in the 1H NMR spectra and at 148.6 ppm in the 13C NMR spectra. Nitrile oxides (R3–CNO; R3 = Ph or CO2Et) were generated from the dehydrochlorination of the corresponding chloroximes, and underwent smooth 1,3-dipolar cycloaddition to dipolarophiles 39a/b to give the previously unreported adducts 40a-d in reasonable yields (47 – 69%). 


Scheme 5: Synthesis of the Oxadiazolo-PBTDs 40
Reagents and Conditions: (a) SOCl2, pyridine, THF, 0 ºC, 3h. (b) CH2=CR1–CR2=CH2. (c) P(OMe)3, Et3N, MeOH, 25 ºC, and then 2 M NaOH (aq). (d) i. HCO2H, (MeCO)2O, THF; ii. P(O)Cl3, (CH2Cl)2.

The successful behaviour of the aromatic pyrrole-containing pyrrolobenzothiadiazepines 39a/b as dipolarophiles towards nitrile oxides prompted us to investigate the use of a series of readily available19,35-38 saturated systems 41 (Figure 2) as dipolarophiles due to the fact that the saturated motif is more common in the naturally occurring PBDs (see Figure 1). To our surprise, we found that the pyrrolo systems (Z = CH2), the homologues (Z = CH2CH2) and the thiazolino analogues (Z = S) were unreactive towards nitrile oxides. Compounds 41 were synthesised as described in the literature using aza-Wittig and other intramolecular cyclisations19,35,36 or thionation37 of the readily available lactams38 followed by alkylation with trimethyloxonium tetrafluoroborate. Interestingly, nitrile oxide cycloadditions to carbon-nitrogen double bonds within bicyclic 1,4-benzodiazepines are known,29 but these have focused on the formation of 1,2,4-oxadiazolino-fused systems by cycloaddition across the 4,5-imino bond rather than the 1,2-imino bond; indeed when both bonds were present, only the 4,5-bond was found to be reactive, supporting our observations with imines 41.



Figure 2: Other Potential Dipolarophiles and 1,3-Dipole Equivalents

Finally, we attempted the reactions of the imines 41 and 39 with cyclopropenones 42, as we had previously39 found that cyclic imines of varying ring size react with cyclopropenones to give fused pyrrolidinones, wherein the cyclopropenone behaves as an all-carbon 1,3-dipole equivalent. We found all of the pyrrolobenzodiazepines and pyrrolobenzothiadiazepine based imines 41 and 39 to be unreactive and that this route did not therefore allow access to pyrrolidinone-fused tetracyclic analogues of the PBDs and PBTDs.

3. Conclusions
We have shown that intramolecular 1,3-dipolar cycloaddition of an azide to a proline-derived nitrile allows access to tetrazolo-fused pyrrolobenzodiazepines and pyrrolobenzothiadiazepines (3 examples). Other amino acids gave 2-amino-1,4-benzodiazepines (2 examples). Attempted intramolecular azide to oxime reaction gave a hydroxyamino pyrrolobenzodiazepine which could not be reacted further meaning that oxadiazolino-fused PBDs or PBTDs were not available via this route. However, oxadiazolino-fused PBTDs were available from intermolecular cycloaddition of nitrile oxides to pyrrolobenzothiadiazepines, although these reactions were only successful when an aromatic pyrrole ring was present (as opposed to the tetrahydropyrrole systems present in the natural pyrrolobenzodiazepines and analogues). The requisite pyrrolobenzothiadiazepines were synthesised by ring contraction of 1,2-thiazine 1-oxides which were in turn produced by hetero-Diels-Alder cycloaddition. Attempts to react imine containing PBTDs and PBDs with cyclopropenones were unsuccessful. We are currently extending the scope of the intramolecular cycloaddition to include alkenes. Given the success of the triazolo-PBTD as a Glut-1 transporter inhibitor, we are also exploring the use of the other tetracyclic PBTD systems discussed in this work as Glut-1 transporter inhibitors. 

4. Experimental section
All reactions were conducted in oven-dried glassware under nitrogen dried through 4 Å molecular sieves and delivered through a gas manifold. Work-up procedures were carried out in air. All solvents were purchased from Fisher Chemicals and were of analytical grade. Anhydrous grade solvents were freshly distilled using a continuous still under nitrogen. Chloroform was dried over 4 Å molecular sieves and distilled over phosphorus pentoxide (3% w/v). Dichloromethane and toluene were distilled over calcium hydride (5% w/v) over 4-6 h. Diethyl ether and THF were pre-dried over sodium wire, and then distilled over sodium wire (1-2% w/v) with benzophenone (0.2-0.3% w/v) as an indicator. Other anhydrous solvents were purchased from Acros or Sigma-Aldrich. All reactions were monitored by TLC, which was carried out on 0.20 mm Macherey-Nagel Alugram® Sil G/UV254 silica gel-60 F254 precoated aluminium plates and visualisation was achieved using UV light and / or vanillin stain. Column chromatography was performed on Merck silica gel (0.063-0.200 mm, 60 Å). NMR spectra were recorded on a Bruker DPX-400 instrument or on a Bruker Avance 500. IR spectra were recorded on a Nicolet 380 FT-IR instrument as a thin film for oils, a drop for liquids or neat for solids. Mass spectra were recorded on a Bruker Daltonics micrOTOF mass spectrometer operating at a positive ion mode under an electrospray ionisation (ESI +) method. High resolution mass spectra were recorded on the same instrument or on a Finnegan MAT 900 XTL instrument operated by the EPSRC National Mass Spectrometry service at the University of Swansea. Melting points were recorded on a Gallenkamp apparatus. Compounds 43 and the precursor lactams were synthesised as described in the literature.19,35-38

4.1. (S)-(1-(2′-Azidobenzenesulfonyl)pyrrolidin-2-yl)methanol 27b

2-Azidobenzenesulfonic acid40 (2.95 g, 14.8 mmol) was heated at reflux in a 2M solution of (COCl)2 in dichloromethane (14.8 mL, 29.6 mmol) with a drop of DMF under an inert atmosphere of nitrogen for 5 hours. The reaction was allowed to reach room temperature before the crude acid chloride was concentrated in vacuo and washed with dichloromethane (3 × 10 mL).
K2CO3 (3.30 g, 23.7 mmol) in water (10 mL) was added in one portion to a stirring solution of L-prolinol (0.60 g, 5.9 mmol) in dichloromethane (15 mL). The crude acid chloride in dichloromethane (10 mL) was added slowly and the whole was stirred for 18 hours at room temperature. The organic layer was separated and the aqueous layer was extracted with ethyl acetate (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered, and concentrated to give the product as a pure orange oil (1.61 g, 96% from prolinol); Rf  = 0.3 (EtOAc:Hex; 4:3); 1H NMR δ (400 MHz, CDCl3): 1.67 - 1.78 (1H, m, CHH), 1.79 - 1.99 (3H, m, CHH + CH2), 2.79 (1H, bs, CH2OH), 3.38 (1H, dt, J 6.3, 10.2, NCHH), 3.49 - 3.56 (1H, m, NCHH), 3.62 (1H, dd, J 5.6, 11.5, CHHOH), 3.70 (1H, dd, J 4.2, 11.5, CHHOH), 4.02 - 4.08 (1H, m, CHCH2OH), 7.27 (1H, ddd, J 1.0, 7.8, 7.8, ArH), 7.32 (1H, dd, J 1.0, 8.0, ArH), 7.62 (1H, ddd, J 1.5, 7.8, 7.8, ArH), 8.02 (1H, dd, J 1.5, 8.0, ArH); 13C NMR δ (100 MHz, CDCl3): 24.7 (CH2), 29.0 (CH2), 49.5 (CH2), 61.8 (CH), 65.5 (CH2), 119.9 (CH), 124.8 (CH), 129.0 (q), 132.6 (CH), 134.2 (CH), 138.2 (q); IR max (thin film cm-1): 819, 870, 900, 928, 992, 1043, 1069, 1122, 1146, 1155, 1199, 1264, 1287, 1323, 1439, 1471, 1574, 1583, 1660, 2120, 2876, 2953, 3172-3693 (br); LRMS (ESI+): Found 305.1 [M + Na]+, 587.1 [2M + Na]+, C11H14N4NaO3S requires 305.1; HRMS (ESI+) : Found 305.0676 [M + Na]+, C11H14N4NaO3S requires 305.0679.

4.2. (S)-(1-(2′-Azidobenzenesulfonyl)pyrrolidin-2-yl)carbaldehyde 18a

A 2M solution of oxalyl chloride in dichloromethane (1.88 mL, 3.75 mmol) was diluted with dichloromethane (10 mL) and cooled to ˗78 C under nitrogen. DMSO (0.53 mL, 0.59 g, 7.5 mmol) in dichloromethane (10 mL) and the alcohol 27b (0.80 g, 2.83 mmol) in dichloromethane (5 mL) were each added over 10 minutes. The whole was maintained at ˗78 C for 30 minutes before dropwise addition of Et3N (2.18 mL, 1.58 g, 15.6 mmol) and the whole was allowed to reach room temp. The reaction was quenched with a mixture of Et2O (10 mL) and H2O (10 mL). The organic layer was separated and the aqueous phase was extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered, concentrated and purified on silica (20g) (EtOAc:Hex; 2:3) to yield the product as a white solid (0.57 g, 72%) which rapidly decomposed to an orange oil and was used immediately in subsequent reactions; Rf  = 0.5 (EtOAc:Hex; 4:3); 1H NMR δ (400 MHz, CDCl3): 1.83 - 1.95 (2H, m, CH2), 1.98 - 2.09 (1H, m, CHH), 2.15 - 2.23 (1H, m, CHH), 3.40 (1H, dt, J 9.7, 7.2, NCHH), 3.57 (1H, ddd, J 5.5, 6.8, 9.7, CHH), 4.47 (1H, ddd, J 1.9, 4.5, 8.5, CHCHO), 7.28 (1H, ddd, J 7.8, 7.8, 1.0, ArH), 7.34 (1H, dd, J 8.0, 1.0, ArH), 7.64 (1H, ddd, J 7.8, 7.8, 1.6, ArH), 8.03 (1H, dd, J 8.0, 1.6, ArH), 9.72 (1H, d, J 1.6, CHO); 13C NMR δ (100 MHz, CDCl3): 25.0 (CH2), 27.7 (CH2), 48.8 (CH2), 67.1 (CH), 119.9 (CH), 124.9 (CH), 128.9 (q), 132.5 (CH), 134.4 (CH), 138.2 (q), 200.5 (CH); max (thin film cm-1): 820, 865, 999, 1080, 1122, 1156, 1199, 1265, 1287, 1332, 1439, 1471, 1574, 1583, 1603, 1730, 2122, 2953; HRMS (ESI+): compound degraded.

4.3. (S)-Pyrrolo[1,2-b][1,2,3]triazolo[5,1-d][1,2,5]benzothiadiazepine 8,8-dioxide 21a

The freshly prepared aldehyde 18a (300 mg, 1.07 mmol) was dissolved in dry methanol (5 mL), K2CO3 (296 mg, 2.14 mmol) and freshly prepared Bestmann-Ohira reagent41 (247 mg, 1.29 mmol) were added and the whole was stirred for 22 hours under nitrogen. The reaction was quenched with saturated aqueous NH4Cl (10 mL), the organic phase was separated and the aqueous phase was extracted with dichloromethane (3 × 10 mL). The combined organic phases were dried (MgSO4), filtered and concentrated under reduced pressure to yield an orange solid. Purification was carried out on a silica column (20g) (EtOAc:Hex; 3:1) to yield the pure product as a pale yellow solid (295 mg, 100%), m.p. 208 – 210 °C. Rf  = 0.3 (EtOAc:Hex; 3:1); 1H NMR δ (400 MHz, CDCl3): 1.63 - 1.73 (1H, m, CHH), 1.88 - 2.09 (2H, m, CH2), 2.27 (1H, dddd, J 2.8, 6.2, 6.2, 12.4, CHH), 3.12 (1H, ddd, J 6.8, 9.9, 9.9, CHHN), 3.68 (1H, ddd, J 2.4, 7.5, 9.9, CHHN), 5.19 (1H, dd, J 6.2, 10.2, NCHCN), 7.62 (1H, ddd, J 1.0, 7.9, 7.9, ArH), 7.79 (1H, s, NCCHN), 7.83 (1H, ddd, J 1.5, 7.8, 7.8, ArH), 8.10 (1H, dd, J 1.5, 7.8, ArH), 8.15 (1H, dd, J 1.0, 7.9, ArH); 13C NMR δ (100 MHz, CDCl3): 24.4 (CH2), 35.4 (CH2), 50.0 (CH2), 55.1 (CH), 125.4 (CH), 128.7 (CH), 129.3 (CH), 130.9 (q), 133.5 (q), 134.1 (CH), 134.4 (CH), 136.8 (q); IR max (cm-1): 814, 974, 1003, 1119, 1170, 1265, 1356, 1457, 1485, 1541, 1558, 1654, 2924, 3735; LRMS (ESI+): Found 299.1 [M + Na]+, 575.2 [2M + Na]+ C12H12N4NaO2S requires 299; HRMS (ESI+): Found 277.0752 [M + H]+, C12H13N4O2S requires 277.0754.

4.4. (S)-1-(2′-Azidobenzoyl)pyrrolidine-2-carbonitrile 28a 

Method A: (CAUTION: ammonia and iodine form nitrogen triiodide which is a contact explosive when dry)

Finely ground iodine (0.39 g, 1.52 mmol) was added portion-wise to a stirred mixture of (S)-(1-(2′-azidobenzoyl)pyrrolidin-2-yl)methanol35 (0.34 g, 1.38 mmol) and ammonia/water solution (10 mL; 7:3 conc. ammonia:water) at ambient temperature. After stirring for 10 minutes, the resultant mixture was heated at 65 – 75 °C for 20 hours. The reaction mixture was cooled to ambient temperature, and was diluted with aqueous sodium sulfite (10 mL) and extracted with diethyl ether (2 × 10 mL). The organic phase was collected, dried over MgSO4, and filtered under gravity. The volatiles were removed under reduced pressure and the crude residue was purified by flash column chromatography (eluent, PE:EtOAc; 2:3) to yield (2S)-1-(2′-azidobenzoyl)-pyrrolidine-2-carbonitrile (0.12 g, 36% yield) as a yellow oil; Rf  = 0.5 (PE:EtOAc; 1:3).

Method B

A solution of 2-azidobenzoic acid42 (710 mg, 4.36 mmol) in thionyl chloride (5 mL) was heated at reflux temperature under a nitrogen atmosphere at 85 C for 3 hours. The reaction mixture was allowed to reach room temperature before excess thionyl chloride was removed under reduced pressure. Washing with dichloromethane (2 × 10 mL) afforded the crude 2-azidobenzoyl chloride as a brown solid which was dissolved in dichloromethane (5 mL). Potassium carbonate (1.03 g, 7.46 mmol) dissolved in water (5 ml), was added in one portion to a stirring solution of (L)-prolinamide (0.20 g, 1.75 mmol) in dichloromethane (5 mL). After stirring for 5 minutes, the solution of 2-azidobenzoyl chloride prepared above was added to the reaction mixture and the resultant mixture was stirred at ambient temperature for 20 hours. Upon completion the reaction mixture was diluted with water (10 mL) and extracted with dichloromethane (2 × 10 mL). The organic phase was collected, dried over MgSO4, and filtered under gravity. The volatiles were removed under reduced pressure and the crude residue was purified by flash silica column chromatography (eluent, PE:EtOAc; 2:3) to yield (2S)-1-(2′-azidobenzoyl)-pyrrolidine-2-carbonitrile (0.20 g, 48% from prolinamide) as a yellow oil; Rf = 0.4 (EtOAc:Hex; 2:1); 1H NMR δ (400 MHz, CDCl3): (rotamers) 2.01 - 2.10 (1H, m, CHH), 2.11 - 2.25 (1H, m, CHH), 2.27 - 2.41 (1H, m, CHH), 3.27 - 3.34 (1H, m, CHH), 3.37 - 3.45 (1H, m, NCHH), 3.72 - 3.83 (1H, m, NCHH), 4.87 (1H, dd, J 8.0, 4.0, CHCN), 7.18 - 7.21 (2H, m, ArH), 7.31 (1H, dd, J 8.0, 4.0, ArH), 7.45 (1H, ddd, J 8.0, 8.0, 4.0, ArH); 13C NMR δ (100 MHz, CDCl3): (rotamers) 22.6/24.3 (CH2), 29.8/31.6 (CH2), 45.1/47.0 (CH2), 45.5/48.2 (CH), 117.4/117.6 (q), 117.9/118.0 (CH), 124.6/124.8 (CH), 127.2 (q), 127.4 (CH), 127.5 (q), 130.5/130.7 (CH), 135.8 (q), 166.5 (q); IR max (thin film cm-1): 732, 756, 904, 1151, 1200, 1291, 1409, 1450, 1488, 1599, 1643, 2131, 2283, 2882, 2982, 3056; LRMS (ESI+): Found 264.1 [M + Na], 288.3 [M + 2Na], 505.1 [2M + Na], C12H11N5NaO requires 264.1; HRMS (ESI+): Found [M + NH4]+ 259.1304, C12H15N6O requires 259.1302; found [M + H]+ 242.1036, C12H12N5O requires 242.1036

4.5. (S)-Pyrrolobenzo[1,2-a]tetrazolo[5,1-c][1,4]diazepin-9-one 29a

A solution of (2S)-1-(2′-azidobenzoyl)-pyrrolidine-2-carbonitrile 28a (0.100 g, 0.41 mmol) in anhydrous toluene (10 mL) under an atmosphere of dry nitrogen was heated at reflux for 6 hours. The reaction mixture was cooled, and evaporation of the solvent gave the crude product as a yellow oil, which was purified by flash chromatography (eluent: PE:EtOAc; 2:3) to yield the tetrazolopyrrolobenzodiazepine (0.099 g, 99% yield) as a pale yellow oil. Rf  = 0.3 (PE:EtOAc; 2:3); 1H NMR δ (400 MHz, CDCl3): 2.16 - 2.40 (2H, m, NCH2CH2), 2.53 - 2.63 (1H, m, CHCHH), 3.16 - 3.23 (1H, m, CHCHH), 3.70 - 3.77 (1H, m, NCHH), 3.85 - 3.91 (1H, m, NCHH), 4.83 (1H, dd, J 8.4, 3.2, CHCN), 7.64 (1H, ddd, J 7.8, 7.8, 0.9, ArH), 7.76 (1H, ddd, J 7.8, 7.8, 1.4 ArH), 7.94 (1H, dd, J 8.0, 0.9, ArH), 8.18 (1H, dd, J 8.0, 1.4 ArH); 13C NMR δ (100 MHz, CDCl3): 23.5 (CH2), 28.2 (CH2), 48.2 (CH2), 49.7 (CH), 122.5 (CH), 127.2 (q), 129.8 (CH), 130.3 (q), 132.3 (CH), 133.1 (CH), 154.5 (q), 163.4 (q); IR max (cm-1): 832, 887, 926, 971, 985, 1023, 1095, 1125, 1151, 1169, 1199, 1241, 1279, 1308, 1353, 1409, 1438, 1470, 1489, 1578, 1605, 1635, 2986, 3039; LRMS (ESI+): Found 264.1 [M + Na], 505.2 [2M + Na] C12H11N5NaO requires 264.1; HRMS (ESI+): Found 242.1034 [M + H]+, C12H12N5O requires 242.1036. 

4.6. (S)-1-(2′-Azidobenzenesulfonyl)-2-prolinamide 24b.

To a suspension of 2-azidobenzenesulfonic acid40 (900 mg, 4.52 mmol) in dichloromethane (5 mL) was added a 2M solution of oxalyl chloride in dichloromethane (6.00 mL, 12.00 mmol) followed by the addition of DMF (50 L). The resultant mixture was heated to reflux temperature for 15 hours under nitrogen. The excess oxalyl chloride was removed under reduced pressure and the residue was washed with dichloromethane (2 × 10 mL) to give the crude sulfonyl chloride as an orange solid. A mixture of potassium carbonate (1.32 g, 9.57 mmol) dissolved in water (10 mL) was added in one portion to L-prolinamide (0.20 g, 1.75 mmol) in dichloromethane (10 mL). The sulfonyl chloride from above was dissolved in dichloromethane (5 mL) and was added dropwise to this solution. The reaction was allowed to stir for 20 hours before the organic layer was separated and the aqueous layer washed with dichloromethane (2 × 10 mL). The combined organic phases were dried (MgSO4), filtered, concentrated in vacuo and purified by silica column chromatography (EtOAc:Hex; 10:1) to yield the product as a pale brown oil (0.33 g, 62% from prolinamide), Rf  = 0.2 (EtOAc:Hex; 10:1); 1H NMR δ (400 MHz, CDCl3): 1.74 - 1.99 (3H, m, CH2 + CHH), 2.31 - 2.40 (1H, m, CHH), 3.26 - 3.38 (1H, m, NCHH), 3.43 - 3.53 (1H, m , NCHH), 4.64 - 4.67 (1H, m, NCH), 5.72 (1H, bs, NH), 6.90 (1H, bs, NH), 7.29 (1H, dd, J 7.7, 7.7, ArH), 7.34 (1H, d, J 8.0, ArH), 7.64 (1H, dd, J 7.7, 7.7, ArH), 8.03 (1H, d, J 8.0, ArH); 13C NMR δ (100 MHz, CDCl3): 24.6 (CH2), 29.7 (CH2), 49.1 (CH2), 62.3 (CH), 119.9 (CH), 124.9 (CH), 127.8 (q), 133.0 (CH), 134.7 (CH), 138.4 (q), 174.2 (q); IR max (cm-1): 1198, 1334, 1446, 1473, 1574, 1670, 2132 (N3), 3350 (br, CONH2); LRMS (ESI+): Found 318.1 [M + Na]+, C11H13N5NaO3S requires 318.1; HRMS (ESI+): Found 313.1077 [M + NH4]+, C11H17N6O3S requires 313.1077.

4.7. (S)-1-(2′-Azidobenzenesulfonyl)pyrrolidine-2-carbonitrile 28b

To a solution of the amide 24b (300 mg, 1.02 mmol) in dichloromethane (5 mL) at room temperature was added pyridine (620 mg, 0.63 mL, 7.84 mmol) followed by neat tosyl chloride (1.27 g, 6.66 mmol). The resultant mixture was heated to reflux temperature under a nitrogen atmosphere for 6 hours. The solvent was removed in vacuo and the crude product was purified on a 20 g silica column (EtOAc: Hex; 1:1) to yield the product as a brown oil (208 mg, 74%); Rf  = 0.4 (EtOAc: Hex; 2:1); 1H NMR δ (500 MHz, CDCl3): 2.06 - 2.34 (4H, m, 2 × CH2), 3.41 - 3.47 (1H, m, NCHH), 3.59 (1H, ddd, J 3.6, 7.6, 9.5, NCHH), 4.95 (1H, dd, J 2.8, 7.2, CH), 7.28 (1H, dd, J 7.7, 7.7, ArH), 7.33 (1H, d, J 8.1, ArH), 7.64 (1H, ddd, J 7.7, 7.7, 1.5, ArH), 8.02 (1H, d, J 8.1, 1.5, ArH); 13C NMR δ (125 MHz, CDCl3): 24.8 (CH2), 32.2 (CH2), 47.7 (CH2), 48.8 (CH), 118.3 (q), 119.8 (CH), 124.7 (CH), 129.0 (q), 131.7 (CH), 134.6 (CH), 138.4 (q); IR max (cm-1): 896, 1016, 1080, 1164, 1200, 1265, 1347, 1422, 1473, 2134, 2305, 2987, 3054, 3583, 3686, 3756; LRMS (ESI+): Found 300.1 [M + Na]+ C11H11N5NaO2S requires 300.1; HRMS (ESI+): Found 295.0972 [M + NH4]+ C11H15N6O2S requires 295.0972.

4.8. (S)-Pyrrolobenzo[1,2-b]tetrazolo[5,1-d][1,2,5]thiadiazepine 9,9-dioxide 29b

(S)-N-(2-Azidobenzenesulfonyl)-pyrrolidine-2-carbonitrile 28b (90 mg, 0.33 mmol) was heated to reflux temperature in dry toluene (8 mL) under a nitrogen atmosphere for 72 hours. The solvent was removed under reduced pressure and the crude product was purified on a 20 g silica column (EtOAc:Hex; 2:1) to yield a white solid (90 mg, 100%), m.p. 179 – 181 °C; Rf  = 0.3 (EtOAc:Hex; 2:1); 1H NMR δ (500 MHz, CDCl3): 1.79 - 1.81 (1H, m, CHH), 1.93 - 1.95 (1H, m, CHH), 2.06 - 2.08 (1H, m, CHH), 2.60 - 2.62 (1H, m, CHH), 3.04 (1H, ddd, J 9.8, 7.5, 7.4, NCHH), 3.64 (1H, ddd, J 4.7, 7.0, 9.8, NCHH), 5.59 (1H, dd, J 7.2, 7.3, NCHC=N), 7.65 (1H, ddd, J 7.8, 7.8, 0.8, ArH), 7.83 (1H, ddd, J 8.0, 8.0, 1.4, ArH), 8.12 (1H, dd, J 7.8, 1.4, ArH), 8.16 (1H, dd, J 8.0, 0.8, ArH); 13C NMR δ (125 MHz, CDCl3): 24.5 (CH2), 34.5 (CH2), 49.3 (CH2), 56.1 (CH), 125.1 (CH), 129.4 (CH), 129.7 (CH), 130.7 (q), 131.1 (q), 134.6 (CH), 155.4 (q); IR max (cm-1): 831, 895, 1070, 1092, 1139, 1174, 1197, 1265, 1363, 1421, 1447, 1482, 1590, 2986, 3054; LRMS (ESI+): Found 278.1 [M + H]+, 577.1 [2M + Na]+, 854.2 [3M + Na]+, C11H12N5O2S requires 278.1; HRMS (ESI+): Found 278.0707 [M + H]+, C11H12N5O2S requires 278.0706.

4.9. (S)-1-(2′-Azido-4′-(benzyloxy)-5′-methoxybenzoyl)pyrrolidine-2-carbonitrile 28c

2′-Azido-4′-(benzyloxy)-5′-methoxybenzoic acid43 (250 mg, 0.84 mmol) was dissolved in toluene (5 mL) and SOCl2 (1.5 mL) was added and the mixture was heated under nitrogen for 3 hours at 85 °C. The reaction mixture was concentrated under reduced pressure, and washed with dichloromethane (2 × 10 mL) to remove excess SOCl2, to yield the crude acid chloride. K2CO3 (193 mg, 1.40 mmol) dissolved in water (3 mL) was added in one portion to a stirring solution of L-prolinamide (40 mg, 0.35 mmol) in dichloromethane (3 mL). After stirring for 30 minutes the acid chloride in dichloromethane (5 mL) was added dropwise and the mixture was stirred overnight. The organic layer was separated and the aqueous layer extracted with dichloromethane (2 × 15 mL). The combined organic layers were dried (MgSO4), filtered and concentrated under reduced pressure to yield a black-brown oil (460 mg). Purification was carried out on silica (40g) (EtOAc:Hex; 3:1) to yield the product as a yellow-orange oil (74 mg, 56% from prolinamide); Rf  = 0.4 (EtOAc:Hex; 5:1); 1H NMR δ (400 MHz, CDCl3): 2.17 - 2.44 (3H, m, CH2 + CHH), 3.39 - 3.52 (2H, m, CH2), 3.75 - 3.82 (1H, m, CHH), 3.94 (3H, s, OCH3), 4.92 (1H, dd, J 3.8, 7.5, NCCHN), 5.24 (2H, s, OCH2), 6.72 (1H, s, ArH), 6.92 (1H, s, ArH), 7.37 - 7.51 (5H, m, ArH); 13C NMR δ (100 MHz, CDCl3): 25.0 (CH2), 30.5 (CH2), 46.4 (CH), 47.7 (CH2), 56.5 (CH3), 71.4 (CH2), 104.4 (CH), 111.3 (CH), 118.4 (q), 120.0 (q), 127.4 (CH), 128.4 (CH), 128.8 (CH), 135.9 (q), 147.4 (q), 150.3 (q), 167.0 (q); IR max (cm-1): 649, 733, 910, 994, 1026, 1078, 1181, 1211, 1245, 1386, 1425, 1453, 1512, 1606, 1638, 2114, 2253, 2937; LRMS (ESI+): Found 377.2 [M]+, 378.2 [M + H]+, C20H20N5O3 requires 378.2; HRMS (ESI+): Found 378.1566 [M + H]+, C20H20N5O3 requires 378.1561.

4.10. (S)-6-(Benzyloxy)-7-methoxybenzopyrrolo[1,2-a]tetrazolo[5,1-c][1,4]diazepin-9-one 29c

The nitrile starting material 28c (50 mg, 0.13 mmol) was heated at reflux under nitrogen in chloroform (10 mL) at 70 °C for 72 hours. The solvent was removed under reduced pressure and purification on silica (20g) (EtOAc: Hex; 3:1) yielded a white solid (29 mg, 58%), m.p. 191 – 194 °C; Rf  = 0.2 (EtOAc:Hex; 3:1); 1H NMR δ (400 MHz, CDCl3): 2.04-2.18 (2H, m, CH2), 2.42-2.52 (1H, m, CHH), 3.06-3.13 (1H, m, CHH), 3.61-3.68 (1H, m, CHH) , 3.73-3.79 (1H, m, CHH), 3.93 (3H, s, OCH3), 4.68 (1H, dd, J 3.2, 8.4, NCCHN), 5.15 (1H, d, J 12.0, OCHH), 5.26 (1H, d, J 12.0, OCHH) 7.19 (1H, s, ArH), 7.25- 7.41 (5H, m, ArH), 7.53 (1H, s, ArH); 13C NMR δ (100 MHz, CDCl3): 23.5 (CH2), 28.2 (CH2), 48.2 (CH2), 49.8 (CH), 56.4 (CH3), 71.3 (CH2), 106.5 (CH), 113.3 (CH), 119.8 (q), 124.2 (q), 127.6 (CH), 128.5 (CH), 128.8 (CH), 135.3 (q), 135.4 (q), 150.3 (q), 151.7 (q), 154.1 (q), 163.4 (q); IR max (thin film cm-1): 755, 791, 1026, 1182, 1221, 1242, 1269, 1374, 1453, 1517, 1606, 1631, 2853, 2924; LRMS (ESI+): Found 377.2 [M]+, 378.2 [M + H]+, C20H20N5O3 requires 378.2; HRMS (ESI+): Found 378.1564 [M + H]+, C20H20N5O3 requires 378.1561.

4.11. 2-(2′-Azidobenzamido)-3-methylbutanenitrile 30a

Step 1: 2-(2′-Azidobenzamido)-3-methylbutanoic acid

2-Azido benzoic acid (396 mg, 2.43 mmol) was heated at reflux under nitrogen at 85 C for 5 hours in SOCl2 (5 mL). The excess SOCl2 was removed under reduced pressure to yield the acid chloride as a crude oil which was re-dissolved in fresh dichloromethane (2 × 10 mL), concentrated under reduced pressure and finally dissolved in fresh dichloromethane (5 mL). K2CO3 (1.34g, 9.72 mmol) in water (5 mL) was added in one portion to (D/L)-valine (711 mg, 6.07 mmol) in dichloromethane (10 mL). The pre-prepared acid chloride in dichloromethane (5 mL) was added dropwise and the whole was stirred for 14 hours. The reaction mixture was acidified with 2M aqueous HCl to pH 2 - 3 and the organic layer was separated. The aqueous phase was extracted with EtOAc (3 × 10 mL), the combined organic layers were dried (MgSO4), filtered, and concentrated under reduced pressure to give a dark brown oil (528 mg, 80%) which was pure and used directly in the next step; 1H NMR δ (400 MHz, CDCl3): 1.06 (3H, d, J 6.8, CH3CHCH3), 1.07 (3H, d, J 6.8, CH3CHCH3), 2.38 (1H, dsept, J 6.8, 4.6, [CH3]2CH), 4.81 (1H, dd, J 8.3, 4.6, NHCHCOOH), 7.22 (1H, dd, J 8.4, 8.4 ArH), 7.25 (1H, d, J 8.4, ArH), 7.52 (1H, ddd, J 7.9, 7.9, 1.5, ArH), 8.11 (1H, bd, J 8.3, CONH), 8.14 (1H, dd, J 7.9, 1.5, ArH); 13C NMR δ (100 MHz, CDCl3): 17.9 (CH3), 19.2 (CH3), 31.1 (CH), 58.0 (CH), 118.4 (CH), 124.1 (q), 125.2 (CH), 132.4 (CH), 132.8 (CH), 137.4 (q), 165.0 (q), 176.0 (q); IR max (cm-1): 909, 1088, 1165, 1216, 1276, 1373, 1393, 1447, 1481, 1553, 1598, 1643, 1719, 2131, 2967, 3365; LRMS (ESI+): Found 285.1 [M + Na]+, 547.2 [2M + Na]+, C12H14N4NaO3 requires 285.1; HRMS (ESI+): Found 285.0945 [M + Na]+, C12H14N4NaO3 requires 285.0958.

Step 2: 2-(2′-Azidobenzamido)-3-methylbutanamide

2-(2′-Azidobenzamido)-3-methylbutanoic acid (322 mg, 1.23 mmol) was dissolved in dry dichloromethane (5 mL), and BOP (544 mg, 1.23 mmol) and Et3N (0.17 mL, 124 mg, 1.23 mmol) were added and the whole was stirred for 10 minutes. Solid NH4Cl (99 mg, 1.85 mmol) and Et3N (0.26 mL, 187 mg, 1.85 mmol) were added and the whole was stirred overnight. The reaction was diluted with dichloromethane (15 mL) and was washed successively with 3M aqueous HCl (3 × 10 mL), saturated NaHCO3 solution (3 × 10 mL) and saturated brine (3 × 10 mL). The organic layer was dried (MgSO4), filtered, concentrated under reduced pressure and purified on silica (23g) (EtOAc:Hex; 2:1) to yield the amide as a yellow solid (293 mg, 91%); Rf  = 0.5 (EtOAc:Hex; 4:1); 1H NMR δ (400 MHz, CDCl3): 1.08 (3H, d, J 6.8, CH3CHCH3), 1.09 (3H, d, J 6.8, CH3CHCH3), 2.35 (1H, dsept, J 6.8, 6.2, [CH3]2CH), 4.60 (1H, dd, J 6.2, 8.3, NHCHCONH2), 5.83 (1H, bs, CONHH), 6.66 (1H, bs, CONHH), 7.25 (1H, dd, J 7.8, 0.9, ArH), 7.27 (1H, ddd, J 7.8, 7.8, 0.9, ArH), 7.55 (1H, ddd, J 7.9, 7.9, 1.6, ArH), 8.00 (1H, bd, J 8.3, CONH), 8.11 (1H, dd, J 7.9, 1.6, ArH); 13C NMR δ (100 MHz, CDCl3): 18.2 (CH3), 19.4 (CH3), 30.7 (CH), 58.8 (CH), 118.4 (CH), 124.6 (q), 125.2 (CH), 132.1 (CH), 132.6 (CH), 137.3 (q), 164.9 (q), 173.4 (q); IR max (cm-1): 747, 984, 1067, 1197, 1297, 1460, 1656, 2129, 2806, 2848, 2894, 2923, 2997, 3200-3600 (br); LRMS (ESI+): Found 284.1 [M + Na]+, 545.2 [2M + Na]+, C12H15N5NaO2 requires 284.1; HRMS (ESI+): Found 284.1111 [M + Na]+, C12H15N5NaO2 requires 284.1118.

Step 3: 2-(2′-Azidobenzamido)-3-methylbutanenitrile 30a

2-(2′-Azidobenzamido)-3-methylbutanamide (533 mg, 2.04 mmol) was dissolved in dry dichloromethane (10 mL). Pyridine (0.83 mL, 808 mg, 10.21 mmol) and tosyl chloride (779 mg, 4.08 mmol) were added and the whole was heated at reflux under nitrogen for 24 hours. The reaction was quenched with saturated aqueous NH4Cl (20 mL) and the organic layer was separated and the aqueous phase was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried (MgSO4), filtered, concentrated under reduced pressure and purified on silica (40g) (EtOAc:Hex;1:3) to yield the product as a yellow solid (199 mg, 40%); Rf  = 0.3 (EtOAc:Hex; 1:3); 1H NMR δ (400 MHz, CDCl3): 1.07 (3H, d, J 6.8, CH3CHCH3), 1.10 (3H, d, J 6.8, CH3CHCH3), 2.11 (1H, dsept, J 6.8, 6.2 [CH3]2CH), 4.92 (1H, dd, J 6.2, 8.4, NHCHCN), 7.14 (1H, d, J 8.0, ArH), 7.18 (1H, dd, J 7.7, 7.7, ArH), 7.48 (1H, ddd, J 7.7, 7.7, 1.6, ArH), 7.97 (1H, bd, J 8.4, CONH), 8.07 (1H, dd, J 8.0, 1.6, ArH); 13C NMR δ (100 MHz, CDCl3): 18.2 (CH3), 18.8 (CH3), 31.6 (CH), 47.1 (CH), 117.8 (q), 118.5 (CH), 123.2 (q), 125.4 (CH), 132.6 (CH), 133.3 (CH), 137.3 (q), 164.1 (q); IR max (cm-1): 754.1, 1089, 1165, 1216, 1277, 1374, 1393, 1447, 1481, 1598, 1522, 1577, 1658, 2131, 2244, 2876, 2928, 2967, 3020, 3200 - 3450 (br); LRMS (ESI+): Found 266.1 [M + Na]+, 509.2 [2M + Na]+, C12H13N5NaO requires 266.1; HRMS (ESI+): Found 266.1012 [M + Na]+, C12H13N5NaO requires 266.1012.

4.12. 2-Amino-3-isopropylbenzo[1,4]diazepin-5(4H)-one 31a

The nitrile 30a (72 mg, 0.30 mmol) was heated at reflux in xylene (10 mL) under nitrogen at 145 °C for 3 days. The solvent was removed under reduced pressure and the crude product was purified on silica (40 g) (EtOAc:Hex; 1:4) to yield an orange oil (34 mg, 55%); Rf  = 0.2 (EtOAc:Hex; 1:4); 1H NMR δ (400 MHz, CDCl3): 1.15 (3H, d, J 6.7, CH3CHCH3), 1.18 (3H, d, J 6.7, CH3CHCH3), 2.16 (1H, dsept, J 6.7, 6.3, CH[CH3]2), 4.98 (1H, dd, J 6.3, 8.4, NHCH), 5.56 (2H, bs, NH2), 6.39 (1H, bd, J 8.4, CHNH), 6.70 (1H, ddd, J 8.1, 8.1, 0.9, ArH), 6.72 (1H, dd, J 8.1, 0.9, ArH), 7.27 (1H, ddd, J 7.8, 7.8, 1.4, ArH), 7.35 (1H, dd, J 7.8, 1.4, ArH); δC (100 MHz, CDCl3): 18.1 (CH3), 18.8 (CH3), 31.8 (CH), 46.6 (CH), 116.7 (CH), 117.6 (CH), 118.0 (q), 127.1 (CH), 128.9 (q), 133.3 (CH), 149.2 (q), 168.4 (q); IR max (cm-1): 1025, 1155, 1260, 1299, 1325, 1377, 1352, 1377, 1394, 1449, 1488, 1539, 1584, 1612, 1635, 2875, 2931, 2962, 3053, 3301, 3382, 3483; LRMS (ESI+): Found 218.1 [M + H]+, C12H16N3O requires 218.1; HRMS (ESI+): Found 218.1283 [M + H]+, C12H16N3O requires 218.1288.

4.13. 2-(2′-Azidobenzamido)-3-phenylpropanenitrile 30b

Step 1: 2-(2′-Azidobenzamido)-3-phenylpropanoic acid

2-Azidobenzoic acid (560 mg, 3.43 mmol) was heated at reflux at 85 C under nitrogen in SOCl2 (8 mL) for 4 hours. The reaction was cooled to room temperature before the excess SOCl2 was removed under reduced pressure to yield the acid chloride as a crude oil which was re-dissolved in fresh dichloromethane (2 × 10 mL), concentrated under reduced pressure and finally dissolved in fresh dichloromethane (5 mL). K2CO3 (1.90g, 13.7 mmol) in water (5 mL) was added in one portion to phenylalanine (963 mg, 5.83 mmol) in dichloromethane (10 mL). The acid chloride in dichloromethane (5 mL) was added dropwise and the whole was stirred overnight before the mixture was acidified to pH 2 with 2M HCl. The organic phase was separated and the aqueous phase was extracted with dichloromethane (3 × 10 mL). The combined organic layers were dried (MgSO4), filtered, concentrated under reduced pressure to give a deep orange oil (1.01g, 95%) that was not purified further. 1H NMR δ (500 MHz, CDCl3): 3.30 (1H, dd, J 14.0, 6.3, PhCHHCH), 3.37 (1H, dd, J 14.0, 5.6, PhCHHCH), 5.10 (1H, dt, J 6.3, 5.6, PhCH2CHNH), 7.16 (1H, d, J 8.0, ArH), 7.25 (1H, dd, J 7.7, 7.7, ArH), 7.27 - 7.38 (5H, m, CH2ArH), 7.51 (1H, ddd, J 7.7, 7.7, 1.6, ArH), 8.06 (1H, bd, J 6.9, NH), 8.16 (1H, dd, J 8.0, 1.6, ArH), 10.26 (1H, bs, COOH); 13C NMR δ (125 MHz, CDCl3): 37.1 (CH2), 54.3 (CH), 118.5 (CH), 123.5 (q), 125.2 (CH), 127.4 (CH), 128.6 (CH), 129.5 (CH), 132.4 (CH), 132.9 (CH), 135.7 (q), 137.4 (q), 164.8 (q), 175.5 (q); IR max (cm-1): 701, 733, 908, 1086, 1166, 1217, 1279, 1447, 1481, 1496, 1532, 1597, 1642, 1724, 2132, 2929, 3030, 3351; LRMS (ESI+): Found 333.1 [M + Na]+, 643.2 [2M + Na]+, C16H14N4NaO3 requires 333.1; HRMS (ESI+): Found 333.0944 [M + Na]+, C16H14N4NaO3 requires 333.0958.

Step 2: 2-(2′-Azidobenzamido)-3-phenylpropanamide

2-(2′-Azidobenzamido)-3-phenylpropanoic acid (325 mg, 1.05 mmol) was dissolved in dry dichloromethane (5 mL), Et3N (0.15 mL, 106 mg, 1.05 mmol) and BOP (464 mg, 1.05 mmol) were added and the whole was stirred for 5 minutes. Solid NH4Cl (84 mg, 1.58 mmol) and Et3N (0.22 mL, 160 mg, 1.58 mmol) were added and, after two hours, the reaction was diluted with dichloromethane (15 mL) and washed with 3M HCl (3 × 10 mL), saturated sodium carbonate solution (3 × 10 mL) and brine (3 × 10 mL). The organic phase was dried (MgSO4), filtered, concentrated under reduced pressure and purified on silica (20g) (EtOAc:Hex; 3:1) to yield the product as a yellow solid (232 mg, 72%); Rf  = 0.2 (EtOAc:Hex; 3:1); 1H NMR δ (400 MHz, CDCl3): 2.96 - 3.05 (2H, m, PhCH2CH), 4.71 (1H, dt, J 6.7, 7.2, PhCH2CH), 5.98 (1H, bs, CONHH), 6.61 (1H, bs, CONHH), 6.90 - 7.10 (7H, m, ArH), 7.28 (1H, ddd, J 7.8, 7.8, 1.6, ArH), 7.75 (1H, dd, J 7.8, 1.6, ArH), 7.82 (1H, bd, J 7.3, NHCHCH2Ph); 13C NMR δ (100 MHz, CDCl3): 37.9 (CH2), 54.8 (CH), 118.5 (CH), 124.7 (q), 125.0 (CH), 126.9 (CH), 128.4 (CH), 129.5 (CH), 131.7 (CH), 132.4 (CH), 136.7 (q), 137.3 (q), 164.6 (q), 173.3 (q); IR max (cm-1): 909, 988, 1047, 1067, 1199, 1249, 1299, 1414, 1479, 1523, 1642, 1696, 2132, 2809, 2848, 2930, 2999, 3190, 3365; LRMS (ESI+): Found 332.1 [M + Na]+, C16H15N5NaO2 requires 332.1; HRMS (ESI+): Found 332.1110 [M + Na]+, C16H15N5NaO requires 332.1118.

Step 3: 2-(2′-Azidobenzamido)-3-phenylpropanenitrile 30b

2-(2′-Azidobenzamido)-3-phenylpropanamide (563 mg, 1.82 mmol) in dry dichloromethane (12 mL) at room temperature was added pyridine (0.74 mL, 721 mg, 9.11 mmol) followed by neat tosyl chloride (694 mg, 3.64 mmol) and the reaction was heated at reflux under nitrogen for 48 hours. The reaction was allowed to cool to room temperature before being quenched with saturated aqueous NH4Cl (30 mL). The organic layer was separated and the aqueous phase was extracted with dichloromethane (3 × 10 mL). The combined organics were dried (MgSO4), filtered, concentrated and purified on silica (24g) (EtOAc:Hex; 2:1) yielding a yellow solid (345 mg, 65%); Rf  = 0.2 (EtOAc:Hex; 2:1); 1H NMR δ (400 MHz, CDCl3): 3.19 (1H, dd, J 6.9, 13.8, PhCHH), 3.29 (1H, dd, J 5.2, 13.8, PhCHH), 5.37 (1H, ddd, J 5.2, 6.9, 7.9, PhCH2CH), 7.19 (1H, dd, J 8.0, 0.8, ArH), 7.28 (1H, ddd, J 7.7, 7.7, 1.0, ArH), 7.37 - 7.46 (5H, m, ArH), 7.56 (1H, ddd, J 7.7, 7.7, 1.6, ArH), 8.04 (1H, bd, J 7.8, CONH), 8.23 (1H, dd, J 8.0, 1.6, ArH); 13C NMR δ (100 MHz, CDCl3): 38.5 (CH2), 42.1 (CH), 118.2 (q), 118.5 (CH), 122.7 (q), 125.4 (CH), 128.2 (CH), 128.9 (CH), 129.8 (CH), 132.8 (CH), 133.4 (CH), 134.0 (q), 137.3 (q), 163.8 (q); IR max (cm-1): 1099, 1150, 1188, 1266, 1296, 1349, 1443, 1483, 1520, 1578, 1597, 1658, 2089, 2128, 3058, 3272; LRMS (ESI+): Found 314.1 [M + Na]+, 605.2 [2M + Na]+, C16H13N5NaO requires 314.1; HRMS (ESI+) : Found 314.1017 [M + Na]+, C16H13N5NaO requires 314.1012.

4.14. 2-Amino-3-benzylbenzo[1,4]diazepin-5(4H)-one 31b

2-(2′-Azidobenzamido)-3-phenylpropanenitrile 30b (141 mg, 0.49 mmol) was heated at reflux in xylene (10 mL) under nitrogen at 145 C for 72 hours. The reaction was allowed to reach room temperature before being concentrated and purified on silica (20g) (EtOAc:Hex; 1:3) giving the product as a yellow oil (72 mg, 56%); Rf  = 0.5 (EtOAc:Hex; 1:2); 1H NMR δ (400 MHz, CDCl3): 3.17 (1H, dd, J 7.2, 13.8, PhCHH), 3.23 (1H, dd, J 5.8, 13.8, PhCHH), 5.21 - 5.24 (1H, ddd, J 8.2, 7.2, 5.8, PhCH2CH), 5.58 (2H, bs, NH2), 6.48 (1H, bd, J 8.2, CONH), 6.63 (1H, dd, J 7.1, 7.1, ArH), 6.69 (1H, d, J 8.2, ArH), 7.19 - 7.45 (7H, m, ArH); 13C NMR δ (100 MHz, CDCl3): 38.8 (CH2), 41.7 (CH), 113.5 (q), 114.8 (CH), 116.7 (CH), 117.6 (q), 127.2 (CH), 128.0 (CH), 128.9 (CH), 129.5 (CH), 133.3 (CH), 134.0 (q), 149.3 (q), 168.3 (q); IR max (cm-1): 747, 880, 898, 1029, 1079, 1097, 1159, 1256, 1295, 1324, 1386, 1454, 1496, 1514, 1586, 1612, 1650, 2853, 2923, 3025, 3357, 3474; LRMS (ESI+): Found 266.1 [M + H]+, 531.3 [2M + H]+ C16H16N5O requires 266.1; HRMS (ESI+): Found 266.1276 [M + H]+, C16H16N5O requires 266.1288.

4.15. 1-(2′-Azidobenzoyl)pyrrolidine-2-carbaldehyde oxime 26a

1-(2′-Azidobenzoyl)pyrrolidine-2-carbaldehyde 18a35 (620 mg, 2.54 mmol), hydroxylamine hydrochloride (265 mg, 3.81 mmol) and sodium acetate (254 mg, 3.10 mmol) were dissolved in ethanol (2.5 mL) and water (3 mL). The resultant solution was heated at reflux for 3.5 hours, cooled to room temperature and the solvent removed under reduced pressure to yield a honey coloured crude sticky oil which was purified using silica gel chromatography (Rf = 0.2; EtOAc:Pet Ether; 2:1) to produce the oxime as a yellow solid (190 mg, 29%), m.p. 133 – 134 °C; 1H NMR δ (400 MHz, CDCl3), mixture of rotamers and isomers: 1.77 - 1.99 (2H, m, CH2), 2.09 - 2.17 (1H, m, CHH), 2.19 - 2.28 (1H, m, CHH), 2.35 - 2.46 (2H, m, CH2), 3.19 - 3.34 & 3.61 - 3.85 (2H, m, CH2), 4.84 - 4.90 (1H, m, NCH), 5.15 - 5.20 (1H, m, CHNOH) , 6.52 & 6.87 (1H, d, J 8.1, ArH), 7.10 - 7.22 & 7.28 - 7.51 (2H, m, ArH), 7.55 (1H, d, J 7.7, ArH), 9.14 & 9.15 (1H, s ,OH); 13C NMR δ (100 MHz, CDCl3), mixture of rotamers and isomers: 22.5/23.5/24.2/25.2 (CH2), 28.9/29.6/30.9/31.1 (CH2), 46.2/46.4/ 48.3/48.6 (CH2), 53.4/53.7/55.8/57.7 (CH), 118.5 (CH), 124.9/ 125.0/125.1/125.2 (CH), 128.01/128.07/128.4/128.7/129.0/129.1 (q), 130.6/130.7 (CH), 136.1/136.2 (q), 149.2/149.9/151.2/152.9 (CH), 167.2/167.4/167.6/167.8 (q); IR υmax (cm-1): 680 (m), 751, 1043, 1148, 1241, 1489, 1596, 2124, 3081, 3246 (br); LRMS (ESI+): Found 282.1 [M + Na]+, 541.2 [2M + Na]+. C12H13N5O2 requires 282.1.

4.16. 11-(Hydroxyimino)benzopyrrolo[1,2-a][1,4]diazepin-5(10H)-one 34a

1-(2′-Azidobenzoyl)pyrrolidine-2-carbaldehyde oxime 26a (155.0 mg, 0.59 mmol) was heated to reflux in dry toluene for 72 hours. The solvent was removed under reduced pressure and purified by silica column chromatography (EtOAc: Pet; 1:3) to afford the product as a white solid (40.2 mg, 30 %), m.p. 106 –  107 °C (deg); 1H NMR δ (500 MHz, CDCl3): 1.72 - 1.99 (2H, m, CH2), 2.56 - 2.75 (2H, m, CH2), 3.46 - 3.65 (2H, m, NCH2), 4.13 (1H, dd, J 3.2, 8.4, NCH), 6.81 (1H, d, J 8.0, ArH), 6.98 (1H, ddd, J 8.0, 8.0, 0.9 ArH), 7.26 (1H, ddd, J 7.8, 7.8, 1.6, ArH), 7.57 (1H, s, NH), 7.76 (1H, dd, J 7.8, 1.6, ArH), 9.60 (1H, s, OH); 13C NMR δ (125 MHz, CDCl3): 20.9 (CH2), 23.5 (CH2), 47.1 (CH2), 54.4 (CH), 120.3 (CH), 122.6 (CH), 125.2 (q), 130.7 (CH), 132.3 (CH), 137.4 (q), 150.2 (q), 166.1 (C=O); IR υmax (thin film) cm-1: 669, 729, 1165, 1243, 1485, 1594, 1610, 1660, 3273 (br); HRMS (ESI+): Found 254.0903 [M + Na]+, C12H13N3NaO2 requires 254.0900.

4.17. 1,2-Thiazine 1-oxides 37a/b

To a solution of 2-azidobenzenesulfonamide40 and thionyl chloride (1.0 molar equivalents) in anhydrous tetrahydrofuran (15 – 30 mL) at 0 °C, under an atmosphere of dry nitrogen, was added a solution of anhydrous pyridine (2.0 molar equivalents) in anhydrous tetrahydrofuran (5 – 10 mL) over a period of 3 hours.  Maintaining the temperature at 0 °C, the stirring was continued for a further 1 hour, followed by dropwise addition of the appropriate 1,3-diene (2.0 molar equivalents), and the whole was allowed to warm up to ambient temperature over 20 hours. After completion of the reaction, the solvent was removed in vacuo and the crude product was purified by flash column silica chromatography (eluent PE:EtOAc; 3:2).

2-(2-Azidobenzenesulfonyl)-3,6-dihydro-5-methyl-1,2-thiazine 1-oxide (37a) was obtained as a yellow solid (1.98 g, 84% yield) from 2-azidobenzenesulfonamide (1.50 g, 7.57 mmol) and isoprene (1.51 mL, 15.14 mmol); m.p. 123 – 124 °C; Rf  = 0.3 (EtOAc:Hex; 4:6); 1H NMR δ (400 MHz, CDCl3): 1.85 (3H, s, CH3), 3.24 (1H, dd, J 16.2, 1.9, CH2SO), 3.61 (1H, dt, J 16.2, 1.1, CH2SO), 3.75 - 3.85 (1H, dm, J 17.0, CH2N), 4.05 - 4.15 (1H, dm, J 17.0, CH2N), 5.65 (1H, d, J 1.9, MeCCH), 7.28 (1H, dd, J 7.6, 7.6, ArH), 7.34 (1H, d, J 8.0, ArH), 7.65 (1H, ddd, J 7.6, 7.6, 1.3, ArH), 8.01 (1H, dd, J 8.0, 1.3, ArH); 13C NMR δ (100 MHz, CDCl3): 24.4 (CH3), 39.3 (CH2), 54.4 (CH2), 117.7 (CH), 120.3 (CH), 122.7 (q), 124.6 (CH), 127.8 (q), 131.6 (CH), 135.1 (CH), 139.1 (q); IR υmax (cm-1): 3023, 2135, 1575, 1473, 1444, 1349, 1293, 1172, 1103, 916, 832, 763, 735, 655, 626; EI+ mass spectrum (m/z, %): 312 ([M]+, 2%), 296 (1%), 284 (3%), 264 (1%), 183 (5%), 171 (10%), 156 (15%), 130 (10%), 108 (15%), 104 (15%), 90 (55%), 84 (45%), 76 (35%), 68 (100%); HRMS (ESI+): found [M+H]+ 313.0416, C11H12N4O3S2 requires 313.0424.

2-(2-Azidobenzenesulfonyl)-3,6-dihydro-4,5-dimethyl-1,2-thiazine 1-oxide (37b) was obtained as a yellow solid (1.89 g, 77% yield) from 2-azidobenzenesulfonamide (1.50 g, 7.57 mmol) and 2,3-dimethyl-1,3-butadiene (1.71 mL, 15.15 mmol); m.p. 137 – 139 °C; Rf  = 0.4 (EtOAc:Hex; 3:6); 1H NMR δ (400 MHz, CDCl3): 1.71 (3H, s, CH3), 1.79 (3H, s, CH3), 3.23 (1H, d, J 16.1, CH2), 3.63 (1H, d, J 14.2, CH2), 3.68 (1H, d, J 14.2, CH2), 3.86 (1H, d, J 16.1, CH2), 7.28 (1H, dd, J 7.8, 7.8, ArH), 7.34 (1H, d, J 8.0, ArH), 7.66 (1H, ddd, J 7.8, 7.8, 1.1, ArH) 8.01 (1H, dd, J 8.0, 0.9, ArH); 13C NMR δ (100 MHz, CDCl3): 16.9 (CH3), 19.7 (CH3), 42.9 (CH2), 55.5 (CH2), 115.0 (q), 120.3 (CH), 123.5 (q), 124.6 (CH), 127.5 (q), 131.6 (CH), 135.1 (CH), 139.0 (q); IR υmax (cm-1): 3006, 2918, 2134, 1585, 1575, 1472, 1444, 1351, 1291, 1171, 1102, 885, 758, 614; EI+ mass spectrum (m/z, %): 326 ([M+H]+, 9%), 298 (12%), 278 (10%), 156 (10%), 116 (25%), 104 (20%), 90 (40%), 76 (35%), 64 (50%), 54 (30%), 39 (100%); HRMS (ESI+): found [M+H]+ 327.0587, C12H14N4O3S2 requires 327.0585.

4.18. 1-(2-Aminobenzenesulfonyl)pyrroles 38a/b

To a rapidly stirring solution of triethylamine (0.15 - 0.40 mL, 1.0 molar equivalents) and trimethylphosphite (0.25 - 0.68 mL, 2.0 molar equivalents) in anhydrous methanol (10 mL) was added the 2-(2-azidobenzenesulfonyl)-3,6-dihydro-1,2-thiazine 1-oxide 37a/b (0.300 - 0.500 g, 1.0 molar equivalents) in one portion and the mixture was stirred at room temperature under an atmosphere of dry nitrogen for 2 hours. The volatiles were removed under reduced pressure and the crude mixture was purified by flash column chromatography (PE:EtOAc; 2:3 + 10% triethylamine). The 1-(2-aminobenzenesulfonyl)pyrroles were obtained as follows:

1-(2-aminobenzenesulfonyl)-3-methylpyrrole (38a) was obtained as a pale yellow oil (0.495 g, 73% yield) from 2-(2-azidobenzenesulfonyl)-3,6-dihydro-5-methyl-1,2-thiazine 1-oxide 37a (0.901 g, 2.88 mmol); Rf = 0.3 (PE:EtOAc; 2:3 + 10% triethylamine); 1H NMR δ (400 MHz, CDCl3): 2.03 (3H, s, CH3), 5.9 – 6.01 (2H, bs, NH2), 6.05 (1H, d, J 2.6, pyrrole-H), 6.75 (1H, dd, J 8.0, 8.0, ArH), 6.89 (1H, d, J 8.4, ArH), 6.93 (1H, s, pyrrole-H), 7.13 (1H, d, J 2.6, pyrrole-H), 7.26 (1H, ddd, J 8.4, 8.4, 1.6, ArH), 7.41 (1H, ddd, J 8.0, 8.0, 1.6, ArH); 13C NMR δ (100 MHz, CDCl3): 11.7 (CH3), 113.1 (CH), 117.8 (CH), 118.5 (CH), 121.6 (CH), 121.8 (q), 124.5 (CH), 128.7 (CH), 129.8 (q), 134.2 (CH), 147.5 (q); IR υmax (thin film cm-1): 3477, 3342, 2999, 2954, 2850, 1591, 1487, 1356, 1291, 1263, 1172, 1031, 914, 816, 760, 732, 677, 607; EI+ mass spectrum (m/z, %): 236 ([M]+, 15%), 156 (19%), 108 (37%), 93 (100%), 65 (84%); C11H12N2O2S requires [M]+ 236; HRMS (ESI+): Found [M + H]+ 237.0734, C11H13N2O2S requires 237.0732.

1-(2-aminobenzenesulfonyl)-3,4-dimethylpyrrole (38b) was obtained as a pale yellow oil (0.135 g, 50% yield) from 2-(2-azidobenzenesulfonyl)-3,6-dihydro-4,5-dimethyl-1,2-thiazine 1-oxide 37b (0.350 g, 1.07 mmol); Rf = 0.3 (PE:EtOAc; 2:3 + 10% triethylamine); 1H NMR δ (400 MHz, CDCl3): 1.91 (6H, s, 2 × CH3), 4.50 - 4.70 (2H, bs, NH2), 6.63 (1H, d, J 8.2, ArH), 6.71 (1H, dd, J 7.5, 7.5, ArH), 6.84 (2H, s, 2 × pyrrole-H), 7.25 (1H, dd, J 7.5, 7.5, ArH), 7.61 (1H, d, J 8.2, ArH); 13C NMR δ (100 MHz, CDCl3): 9.6 (CH3), 10.1 (CH3), 117.4 (CH), 117.6 (CH), 117.8 (CH), 120.0 (q), 124.2 (q), 129.2 (CH), 135.0 (CH), 145.6 (q); IR υmax (cm-1): 3457, 3377, 2966, 2919, 1599, 1484, 1455, 1348, 1296, 1068, 1034, 829, 744, 699, 610, 588; EI+ mass spectrum (m/z, %): 250 ([M]+, 70%), 185 (25%), 156 (20%), 108 (35%), 94 (100%), 65 (80%), 39 (50%); C12H14N2O2S requires [M]+, 250; HRMS (ESI+): Found [M + H]+ 251.0845, C12H15N2O2S requires 251.0849.

4.19. Synthesis of Pyrrolobenzothiadiazepines 39a/b

Step 1: N-formylation

Formic acid (0.036 - 0.193 g, 2.25 molar equivalents) was added to acetic anhydride (0.070 - 0.381 g, 2.0 molar equivalents) at 0 °C and the solution was stirred at room temperature for 2 hours. This solution was added to a solution of the 1-(2-aminobenzenesulfonyl)pyrrole 38a/b (1.0 molar equivalents) in anhydrous tetrahydrofuran (5 mL) and the reaction mixture was stirred at room temperature for 20 hours. The volatiles were removed under reduced pressure and the crude mixture was purified by flash silica column chromatography (PE:EtOAc; 2:3).

1-(2-formamidobenzenesulfonyl)-3-methylpyrrole was obtained as pale yellow oil (0.383 g, 77% yield) from 1-(2-aminobenzenesulfonyl)-3-methylpyrrole (38a; 0.440 g, 1.86 mmol); Rf = 0.2 (PE:EtOAc; 2:3); 1H NMR δ (400 MHz, CDCl3): 2.05 (3H, s, CH3), 6.16 (1H, s, pyrrole-H), 6.85 (1H, s, pyrrole-H), 7.05 (1H, dd, J 2.6, 2.6, pyrrole-H), 7.23 (1H, dd, J 7.9, 7.9, ArH), 7.31 (1H, d, J 7.6, ArH), 7.59 (1H, dd, J 7.6, 7.6, ArH), 7.79 (1H, d, J 7.9, ArH), 8.54 (1H, s, CHO), 9.40 (1H, br s, NH); 13C NMR δ (100 MHz, CDCl3): 11.8 (CH3), 116.5 (CH), 117.4 (CH), 120.5 (CH), 123.2 (CH), 124.6 (CH), 125.4 (q), 126.0 (q), 128.8 (CH), 129.9 (q), 135.3 (CH), 158.9 (CHO); IR υmax (cm-1): 3299, 2953, 1705, 1677, 1580, 1517, 1467, 1433, 1406, 1361, 1291, 1261, 1174, 1096, 1038, 913, 829, 735, 692, 608; EI+ mass spectrum (m/z, %): 264 ([M]+, 50%), 184 (77%), 156 (45%), 120 (59%), 92 (81%), 81 (100%), 65 (95%), 53 (83%). C12H12N2O3S requires [M]+ 264; HRMS (CI + NH3): Found [M + NH4]+ 282.0905, C12H16N3O3S requires 282.0907.

1-(2-formamidobenzenesulfonyl)-3,4-dimethylpyrrole was obtained as pale yellow oil (0.120 g, 83% yield) from 1-(2-aminobenzenesulfonyl)-3,4-dimethylpyrrole (38b; 0.130 g, 0.52 mmol); Rf = 0.2 (PE:EtOAc; 2:3); 1H NMR δ (400 MHz, CDCl3): 1.97 (6H, s, 2 × CH3), 6.85 (2H, s, 2 × pyrrole-H), 7.23 (1H, dd, J 7.7, 7.7, ArH), 7.61 (1H, dd, J 7.7, 7.7, ArH), 7.77 (1H, d, J 8.0, ArH), 8.52 (1H, d, J 8.0, ArH), 8.56 (1H, s, CHO), 9.45 (1H, br s, NH); 13C NMR δ (100 MHz, CDCl3): 10.1 (CH3), 117.5 (CH), 123.0 (CH), 124.2 (CH), 125.7 (q), 125.8 (CH), 126.1 (q), 128.8 (CH), 135.1 (CH), 158.8 (CHO); IR υmax (cm-1): 3290, 3020, 2921, 1706, 1674, 1579, 1514, 1403, 1358, 1290, 1216, 1160, 1071, 669; EI+ mass spectrum (m/z, %): 278 ([M]+, 60%), 250 (10%), 228 (60%), 184 (85%), 156 (20%), 120 (50%), 95 (100%), 65 (85%). C13H14N2O3S requires [M+] 278; HRMS (CI + NH3): Found [M + NH4]+ 296.1063, C13H18N3O3S requires 296.1063.

Step 2: Ring Closure

A solution of the 1-(2-formamidobenzenesulfonyl)pyrrole (1.0 molar equivalents) and phosphorus oxychloride (0.67 - 0.93 mL, 20 - 25 molar equivalents) in dichloroethane (2 mL) was heated at reflux temperature for 3 hours. Saturated sodium hydrogen carbonate solution (4 mL) and ethyl acetate (4 mL) were added and the organic layer was separated and dried over Na2SO4. Evaporation of the solvent gave a residue, which was purified by flash silica column chromatography (PE:EtOAc; 2:3). 

The pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxides were obtained as follows:

1-Methyl-pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39a) was obtained as pale yellow oil (0.067 g, 59% yield) from 1-(2-formamidobenzenesulfonyl)-3-methylpyrrole (0.121 g, 0.46 mmol); Rf = 0.2 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 2.37 (3H, s, CH3), 6.36 (1H, d, J 2.9, pyrrole-H), 7.44 (1H, dd, J 7.4, 7.4, ArH), 7.51 (1H, d, J 2.9, pyrrole-H), 7.66 - 7.75 (2H, m, 2 × ArH), 8.07 (1H, d, J 7.9, ArH), 8.66 (1H, s, N=CH); 13C NMR δ (100 MHz, CDCl3): 11.5 (CH3), 114.8 (CH), 123.0 (q), 123.1 (CH), 124.6 (q), 125.5 (CH), 126.5 (CH), 129.9 (CH), 133.0 (q), 134.6 (CH), 143.9 (q), 148.6 (N=CH); IR υmax (cm-1): 2927, 1603, 1580, 1466, 1365, 1259, 1187, 1149, 1069, 910, 829, 765; ES+ mass spectrum (m/z, %): 247 ([M + H]+, 100%), 172 (54%), 130 (45%), 112 (33%), 88 (15%), 58 (15%), C12H11N2O2S requires 247; HRMS (ES+): Found [M + H]+, 247.0532, C12H11N2O2S requires 247.0536.

1,2-Dimethyl-pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39b) was obtained as pale yellow oil (0.040 g, 43% yield) from 1-(2-formamidobenzenesulfonyl)-3,4-dimethylpyrrole (c; 0.100 g, 0.36 mmol); Rf = 0.2 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 2.06 (3H, s, CH3), 2.26 (3H, s, CH3), 7.33 (1H, s, pyrrole-H), 7.42 (1H, ddd, J 8.0, 8.0, 1.0, ArH), 7.60 - 7.73 (2H, m, 2 × ArH), 8.04 (1H, dd, J 8.0, 1.2, ArH), 8.62 (1H, s, N=CH); 13C NMR δ (100 MHz, CDCl3): 9.6 (CH3), 9.9 (CH3), 120.8 (CH), 123.6 (q), 124.9 (q), 125.3 (CH), 126.2 (CH), 129.9 (CH), 130.1 (q), 132.5 (q), 134.4 (CH), 144.1 (q), 148.6 (N=CH); IR υmax (cm-1): 2924, 1603, 1582, 1458, 1365, 1294, 1181, 1137, 1107, 910, 832, 767; ES+ mass spectrum (m/z, %): 261 ([M + H]+, 100%), 86 (4%), 58 (25%); HRMS (ESI+): Found [M + H]+ 261.0691, C13H13N2O2S requires 261.0692.

4.20. Synthesis of 11-phenyl-[1,2,4-oxadiazolo]pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxides 40a-d

Typical Procedure: A solution of benzohydroximoyl chloride or ethyl chloroximidoacetate (1.00 – 2.00 mmol, 2.2 molar equivalents) in tetrahydrofuran (10 – 20 mL) was added dropwise over 10 - 12 hours, with stirring, to a mixture of the pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39a/b; 0.50 – 1.00 mmol, 1.0 molar equivalents) and triethylamine (1.00 – 2.00 mmol, 2.2 molar equivalents) in anhydrous tetrahydrofuran (10 – 20 mL) at ambient temperature. After stirring at room temperature for a further 10 - 12 hours, the volatiles were removed under reduced pressure and the crude residue was purified by flash column chromatography (PE:EtOAc; 1:2). 

11-Phenyl-[1,2,4-oxadiazolo]-1-methylpyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (40a) was obtained as a pale yellow oil (0.085 g, 47% yield) from the pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39a, 0.121 g, 0.49 mmol); Rf = 0.3 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 2.21 (3H, s, CH3), 6.14 (1H, d, J 3.2, pyrrole-H), 6.85 (1H, d, J 3.2, pyrrole-H), 7.10 (1H, s, CHON), 7.20 - 7.30 (2H, m, 2 × ArH), 7.30 - 7.50 (4H, m, 4 × ArH), 7.57 (2H, d, J 7.7, 2 × ArH), 7.94 (1H, dd, J 7.9, 1.4, ArH); 13C NMR δ (100 MHz, CDCl3): 11.8 (CH3), 91.9 (CHON), 115.5 (CH), 119.5 (q), 122.3 (CH), 124.4 (q), 125.5 (CH), 127.4 (CH), 127.7 (CH), 127.8 (q), 128.5 (CH), 128.8 (CH), 131.1 (CH), 132.8 (q), 134.4 (CH), 135.9 (q), 155.6 (q); IR υmax (cm-1): 3145, 3087, 3066, 2927, 1660, 1585, 1477, 1444, 1408, 1358, 1258, 1179, 1156, 1089, 908, 836, 730, 694, 648; ES+ mass spectrum (m/z, %): 366 ([M + H]+, 27%), 191 (21%), 132 (35%), 117 (26%), 85 (100%), C19H16N3O3S requires 366; HRMS (ESI+): Found [M + H]+ 366.0905, C19H16N3O3S requires 366.0907.

11-Phenyl-[1,2,4-oxadiazolo]-1,2-dimethylpyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (40b) was obtained as pale yellow oil (0.201 g, 69% yield) in the same way from 1,2-dimethyl-pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39b; 0.202 g, 0.78 mmol); Rf = 0.3 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 1.93 (3H, s, CH3), 2.10 (3H, s, CH3), 6.81 (1H, d, J 8.0, ArH), 7.07 (1H, s, CHON), 7.23 (1H, dd, J 7.2, 7.2, ArH), 7.30 - 7.40 (4H, m, 3 × ArH + pyrrole-H), 7.45 (1H, dd, J 7.5, 7.5 ArH), 7.56 (2H, d, J 7.9, 2 × ArH), 7.90 (1H, d, J 7.9, ArH); 13C NMR δ (100 MHz, CDCl3): 9.5 (CH3), 10.0 (CH3), 92.0 (CH), 119.6 (q), 119.8 (CH), 124.2 (q), 124.5 (q), 125.3 (CH), 127.3 (CH), 127.5 (CH), 128.2 (q), 128.4 (CH), 128.7 (q), 128.8 (CH), 131.1 (CH), 132.6 (q), 134.2 (CH), 135.9 (q); IR υmax (cm-1): 3145, 3090, 3070, 1610, 1584, 1573, 1500, 1446, 1409, 1365, 1308, 1269, 1197, 1185, 1174, 1130, 1085, 905, 842, 774, 699; ES+ mass spectrum (m/z, %): 380 ([M + H]+, 100%), 303 (10%), 277 (13%), 261 (35%), 249 (18%), 175 (10%), 141 (12%), 105 (18%), 89 (11%); HRMS (ESI+): Found [M + H]+ 380.1063, C20H18N3O3S requires 380.1067.

Ethyl [1,2,4-oxadiazolo]-1-methylpyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide 11-carboxylate (40c) was obtained as a pale yellow oil (0.190 g, 66% yield) from 1-methylpyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39a; 0.203 g, 0.82 mmol); Rf = 0.2 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 1.28 (3H, t, J 7.1, CO2CH2CH3), 2.12 (3H, s, CH3), 4.25 (2H, m, CO2CH2CH3), 6.13 (1H, s, CHON), 7.11 (1H, s, pyrrole-H), 7.33 (1H, d, J 3.0, pyrrole-H), 7.54 (1H, dd, J 7.7, 7.7, ArH), 7.63 (1H, d, J 7.7, ArH), 7.70 (1H, dd, J 7.7, 7.7, ArH), 7.95 (1H, d, J 7.7, ArH); 13C NMR δ (100 MHz, CDCl3): 11.2 (CH3), 13.8 (CH3), 62.7 (CH2), 91.3 (CH), 114.0 (CH), 121.1 (q), 123.9 (CH), 127.1 (CH), 129.0 (CH), 130.2 (q), 133.6 (CH), 134.5 (CH), 137.8 (q), 147.8 (q), 156.6 (q); IR υmax (cm-1): 3159, 3100, 3020, 2926, 1736, 1574, 1485, 1444, 1416, 1362, 1287, 1259, 1214, 1193, 1153, 1094, 1020, 913, 763; ES+ mass spectrum (m/z, %): 362 ([M + H]+, 100%), 316 (10%), 282 (16%), 247 (15%), 89 (24%), 59 (16%), C16H16N3O5S requires 362; HRMS (ESI+): Found [M + H]+ 362.0804, C16H16N3O5S requires 362.0805.

Ethyl [1,2,4-oxadiazolo]-1,2-dimethylpyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide 11-carboxylate (40d) was obtained in a similar manner as a pale yellow oil (0.101 g, 58% yield) from 3,5-dimethyl-pyrrolo[1,2-b][1,2,5]benzothiadiazepine 5,5-dioxide (39b; 0.120 g, 0.46 mmol); Rf = 0.2 (PE:EtOAc; 1:2); 1H NMR δ (400 MHz, CDCl3): 1.30 (3H, t, J 7.1, CO2CH2CH3), 1.93 (3H, s, CH3), 2.01 (3H, s, CH3), 4.23 - 4.31 (2H, m, CO2CH2CH3), 7.10 (1H, s, pyrrole-H), 7.14 (1H, s, CHON), 7.52 (1H, ddd, J 7.7, 1.1, 1.1, ArH), 7.60 (1H, dd, J 7.9, 1.1, ArH), 7.68 (1H, ddd, J 7.7, 7.7, 1.5, ArH), 7.95 (1H, dd, J 7.9, 1.5, ArH); 13C NMR δ (100 MHz, CDCl3): 9.3 (CH3), 9.9 (CH3), 13.8 (CH3), 62.7 (CH2), 91.6 (CH), 121.0 (q), 121.5 (CH), 122.7 (q), 127.0 (CH), 128.9 (CH), 130.5 (q), 133.5 (CH), 134.2 (CH), 138.0 (q), 147.9 (q), 156.6 (q); IR υmax (cm-1): 3175, 3111, 3013, 2931, 1733, 1582, 1362, 1310, 1275, 1205, 1186, 1130, 1080, 1018, 903, 818, 786, 764; ES+ mass spectrum (m/z, %): 376 ([M + H]+, 41%), 262 (17%), 261 (100%), 74 (14%), C17H18N3O5S requires 376; HRMS (ESI+): Found [M + H]+ 376.0962, C17H18N3O5S requires 376.0966.
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